Clinical trial NCT02188862: Genetic Susceptibility to Rheumatic Heart Disease in the Pacific Region
Official title: Genome-wide Association Study of Susceptibility to Rheumatic Heart Disease in Fiji and New Caledonia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Rheumatic Heart Disease
Mitral Stenosis
Keywords: Rheumatic heart disease
Acute rheumatic fever
Group A streptococcal disease
Streptococcus pyogenes
Genetics
Oceania
Lead sponsor: University of Oxford
Sponsor class: OTHER
Collaborators: name: Ministry of Health, Fiji
name: Fiji National University
name: Institut National de la Santé Et de la Recherche Médicale, France
name: Institut Necker Enfants Malades
name: Centre Hospitalier Territorial de Nouvelle-Calédonie
name: University of Melbourne
First posted: 2014-07-14
Enrollment: 2372
Sex: ALL
Minimum age (years): 5
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Cases:

* Prevalent and incident cases of rheumatic heart disease ascertained from disease registers, primary care clinics and hospital services.

New Controls:

* Individuals volunteering from communities where cases were identified.

Existing Controls:

* Individuals from this region who have previously been recruited to population genetics research studies.

Brief summary: The purpose of this study is to investigate whether there are genetic differences between patients with rheumatic heart disease and members of the general population.

Detailed description: The investigators will micro-array genotype approximately 300,000 single nucleotide polymorphisms (SNP) using DNA samples from patients with rheumatic heart disease (cases) from New Caledonia and Fiji, and members of the general population (controls) from New Caledonia, Vanuatu and Fiji. The investigators will perform standard quality control checks on the SNP data using measures such as call rate, heterozygosity, duplication and relatedness, and exclude variants on the basis of deviation from Hardy-Weinberg equilibrium and minor allele frequency. We will also impute variants not present on the micro-array with reference to the latest release of 1000 Genomes data and whole-genome sequence data from sixty Melanesian individuals from New Caledonia from the phenotypic extremes in this study.

The investigators will conduct a discovery analysis in using a genome-wide association study approach focusing on Oceanic cases and controls from the Francophone nations of New Caledonia and Vanuatu. This analysis will be corrected for bias due to population stratification using the Linear Mixed Model (LMM) and consider additive, dominant and recessive genetic models. The investigators will then perform LMM association testing for variants with P-value in the discovery analysis less than 1x10\^-5 in Oceanic cases and controls from Fiji and combine the association statistics by fixed-effects meta-analysis. The investigators will consider variants with significant effects in the same direction in discovery and replication analyses with combined P-value less than 1x10\^-8 to have replicated. Unless there is clear evidence that associated variants are specific to Oceanic populations, further replication analyses for associated variants in cases and controls of Indian Descent from Fiji, as well as individuals of other and admixed ethnicities from both Fiji and New Caledonia.

Recruitment completed in December 2013. After receipt of funding from the British Heart Foundation, genotyping and analysis will begin in July 2014.

Eligibility criteria: 1. Cases

   1. Inclusion Criteria:

      * Diagnosis of rheumatic heart disease based on one of:

        * World Heart Federation definite echocardiographic criteria
        * World Heart Federation borderline echocardiographic criteria and history of acute rheumatic fever
        * Mitral stenosis with valve area less than 2.0 cm2
        * Previous surgery for rheumatic heart disease
   2. Exclusion Criteria:

      * Age less than five years
      * Inability to give consent
2. New Controls

   1. Inclusion criteria:

      * Healthy individual living in a community where cases were identified
   2. Exclusion Criteria:

      * Past medical history or systems suggestive of rheumatic heart disease, acute rheumatic fever or other valvular heart disease
      * Age less than five years
      * Inability to give consent

Primary outcomes:
measure: Rheumatic heart disease diagnosis
timeFrame: At enrolment
Secondary outcomes:
measure: Mitral stenosis diagnosis
timeFrame: At enrolment
Other outcomes:
Locations:
city: Suva
country: Fiji
facility: Colonial War Memorial Hospital
city: Noumea
country: New Caledonia
facility: Centre Hospitalier Territorial de Nouvelle Caledonie
city: Oxford
country: United Kingdom
facility: Wellcome Trust Centre for Human Genetics, University of Oxford
Study officials:
affiliation: University of Oxford
name: Tom Parks, MRCP DTM&H
role: PRINCIPAL_INVESTIGATOR
affiliation: Institut National de la Santé Et de la Recherche Médicale, France
name: Mariana Mirabel, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Melbourne
name: Andrew C Steer, FRACP PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Oxford
name: Adrian VS Hill, DPhil DM
role: STUDY_CHAIR
References: